Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. (2020)

• Record Type: Book
• Further Information: Note: Renato Alberto Sinico, Loïc Guillevin, editors.
• Other Names: Sinico, Renato Alberto; Guillevin, L (Loïc)
• Contents: Intro; Acknowledgements; Contents; Part I: ANCA-Associated Vasculitis; 1: Introduction: Nomenclature and Classification; 1.1 AAV Pathologic Features; 1.2 Historical Background; 1.3 Vasculitis Nomenclature and Classification; 1.4 Classification and Diagnosis of AAV; 1.5 Both Serotype and Phenotype Are Useful for Classification and Diagnosis; 1.6 Concluding Remarks; References; 2: Genetics of ANCA-Associated Vasculitis; 2.1 Introduction; 2.1.1 Why Study the Genetics of AAV; 2.2 Molecular Genetic Approaches; 2.3 Genetics of GPA and MPA; 2.4 Genetics of EGPA 2.5 Contribution of Genetics to Better AAV Classification2.6 Genetics and Prognosis; 2.7 Conclusion; References; 3: Etiopathogenesis of ANCA-Associated Vasculitis; 3.1 Introduction; 3.2 Genesis of the ANCA Autoimmune Response; 3.2.1 Molecular Mimicry Theory; 3.2.2 Complementary Peptides; 3.2.3 NETosis; 3.2.4 T-Cell Dysregulation and MPO/PR3 Autoimmunity; 3.3 Evidence for the Pathogenic Role of ANCAs; 3.3.1 Clinical Support for ANCA Pathogenicity; 3.3.2 In Vitro Support for ANCA Pathogenicity; 3.3.3 Animal Model Supports ANCA Pathogenicity 3.3.4 Mechanisms of ANCA-Induced Lesions: The Role of Complement3.4 Conclusion: Pathogenic Mechanism Overview; References; 4: ANCA: Methods and Clinical Significance; 4.1 Introduction; 4.2 Detection of ANCA in Small-Vessel Vasculitis; 4.3 Revised 2017 International Consensus on ANCA Testing in Small-Vessel Vasculitis; 4.4 Clinical Usefulness of ANCA Testing; 4.4.1 Gating Policy; 4.4.2 Utility of ANCA in Managing Disease Activity and Guidance Therapy; 4.5 Proteinase 3-ANCA and Myeloperoxidase-ANCA Subtype: Useful Tool for Disease Classification in Small-Vessel Vasculitis 4.5.1 Epidemiological and Genetic/Epigenetic Features vs. ANCA Specificity4.5.2 ANCA Specificity and Clinical/Histological Features; 4.6 Conclusion; References; 5: Activity and Damage; 5.1 Introduction; 5.2 How Can Laboratory Measures Help?; 5.3 Clinical Disease Activity and Damage Measures; 5.4 Disease Activity Assessment in Vasculitis; 5.4.1 BVAS, BVAS WG, and PVAS; 5.5 Assessment of Damage in Vasculitis; 5.5.1 VDI; 5.5.2 Main Differences When Scoring VDI Versus BVAS v3; 5.5.3 Key Points About VDI; 5.6 Role of Assessment of Disease Status in AAV; 5.7 Patient-Reported Outcomes 5.8 Training5.9 Future; 5.10 Conclusions; References; 6: Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss); 6.1 Introduction; 6.2 Epidemiology; 6.3 Triggering Factors; 6.4 Pathophysiology; 6.5 Clinical Manifestations; 6.5.1 General Symptoms; 6.5.2 Pulmonary and Ear, Nose, and Throat (ENT) Manifestations; 6.5.3 Neurological Manifestations; 6.5.4 Skin Manifestations; 6.5.5 Gastrointestinal Involvement; 6.5.6 Cardiac Manifestations; 6.5.7 Renal Manifestations; 6.5.8 Other Manifestations; 6.6 Complementary Investigations; 6.7 Diagnosis
• Publisher Details: Cham : Springer
• Publication Date: 2020
• Extent: 1 online resource (334 pages)
• Subjects: 616.13; Vasculitis; Vasculitis; Electronic books
• Languages: English
• ISBNs: 9783030022396; 3030022390
• Notes: Note: Includes bibliographical references and index.; Note: Online resource; title from PDF title page (SpringerLink, viewed September 23, 2019).
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.